Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4173588 | 0.88 | PTGS2 (0.38) | HPGDKMT2ARXRAALDH1A1NR4A2 | |
| SCHEMBL4159114 | 0.79 | NR4A2 (0.33) | HPGDALDH1A1NR4A2 | |
| SCHEMBL4161696 | 0.78 | CCNC (0.39) | KMT2AALDH1A1 | |
| SCHEMBL4161630 | 0.74 | NR4A2 (0.31) | ALDH1A1NR4A2 | |
| SCHEMBL4166440 | 0.73 | MAPT (0.52) | HPGDKMT2AALDH1A1 | |
| SCHEMBL2076088 | 0.72 | NR4A2 (0.35) | ALDH1A1NR4A2 | |
| SCHEMBL4159231 | 0.70 | KDM4E (0.43) | KMT2AALDH1A1NR4A2 | |
| SCHEMBL4800668 | 0.68 | HPGD (0.34) | HPGDNR4A2 | |
| SCHEMBL4167350 | 0.68 | NR4A2 (0.32) | HPGDNR4A2 | |
| SCHEMBL2075029 | 0.68 | JAK2 (0.42) | HPGDKMT2AALDH1A1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | HPGD 1700/4885KMT2A 1239/4885RXRA 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.